Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Ida Löfman"'
Autor:
Ida Löfman, Karolina Szummer, Henrik Olsson, Juan‐Jesus Carrero, Lars H. Lund, Tomas Jernberg
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 14 (2018)
Background There are no studies of mineralocorticoid receptor antagonist (MRA) treatment examining outcome in unselected real‐life patients with myocardial infarction (MI) and heart failure (HF). There is uncertainty regarding effects of MRA in rel
Externí odkaz:
https://doaj.org/article/f8430b5ef23a499083a49db5439bc5a9
Autor:
Emily de Coursey, Marie Felldin, John Mackay Søfteland, Susannah Leach, Jesper Magnusson, Gustav Friman, Bengt von Zur-Mühlen, Ali Reza Biglarnia, Hanna Jacobsson, Kristjan Karason, Ida Löfman, Vanda Friman, Andreas Schult, Bo-Göran Ericzon, Carin Wallquist, Per Lindnér, Mihai Oltean, Jan Ekelund, Jan-Åke Liljeqvist
Publikováno v:
American Journal of Transplantation
Solid organ transplant (SOT) recipients run a high risk for adverse outcomes from COVID-19, with reported mortality around 19%. We retrospectively reviewed all known Swedish SOT recipients with RT-PCR confirmed COVID-19 between March 1 and November 2
Autor:
Ana Dugic, Apostolos V Tsolakis, Corinna Steiner, Miroslav Vujasinovic, Ida Löfman, J-Matthias Löhr, Sara Nikolic
Publikováno v:
World Journal of Gastroenterology
Background It has been suggested that chronic pancreatitis (CP) may be an independent risk factor for development of cardiovascular disease (CVD). At the same time, it seems that congestive heart failure (CHF) and CP share the responsibility for the
Autor:
Soulmaz Fazeli Farsani, Kimberly G. Brodovicz, Camilla Settergren, Gianluigi Savarese, Lars H. Lund, Linda Mellbin, Francesco Cosentino, Folkert W. Asselbergs, Martina Brueckmann, Andrea Meyers, Ulrik Sartipy, B. Schrage, Ulf Dahlström, Tonje Thorvaldsen, Ida Löfman, Ola Vedin
Publikováno v:
International Journal of Cardiology
Background: Comorbidities may differently affect treatment response and cause-specific outcomes in heart failure (HF) with preserved (HFpEF) vs. mid-range/mildly-reduced (HFmrEF) vs. reduced (HFrEF) ejection fraction (EF), complicating trial design.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::296a9716c6658fc7b9efb9cf94c78072
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-170688
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-170688
Autor:
Ida Löfman, Erica Ottenblad, Aristomenis Manouras, Emil Najjar, Lars H. Lund, Marcus Stålhberg, Camilla Hage
Publikováno v:
ESC Heart Failure. 5:302-308
AIMS Levosimendan improves haemodynamics in acute decompensated heart failure (HF). However, it is increasingly used for repetitive or intermittent infusions in advanced but stable chronic HF, without clear indication, selection criteria, or effect.
Autor:
Toni Sarapohja, Fabrizio Morandi, Paola Beltrán, Gerhard Pölzl, Roman Pfister, Matti Kivikko, Piero Pollesello, Johann Altenberger, Dirk von Lewinski, Mirko Seidel, Gian Piero Perna, Josep Comín-Colet, Attila Borbély, Ramón Bover, Martín J. García-González, Friedrich Fruhwald, George Giannakoulas, Loant Baholli, Martin Martínez-Sellés, Alexander Reinecke, Bojan Vrtovec, Juan F. Delgado, Gabriella Malfatto, Alejandro Recio-Mayoral, Josep Masip, Stefan Störk, Fabrizio Oliva, Gregory Giamouzis, Finn Gustafsson, Patrik Yerly, Diego Rangel-Sousa, Kari Kaikkonen, Ida Löfman, Zoltán Papp, Henning Mølgaard, Gunter Schmidt, Nicolás Manito, Antonella Fontana, Francesco Fedele, Gerhard Wikström, Vito Piazza, Emil Pantev, Béla Merkely, Jacek Kubica, Andreas Rieth
Publikováno v:
Poelzl, G, Altenberger, J, Baholli, L, Beltran, P, Borbely, A, Comin-Colet, J, Delgado, J F, Fedele, F, Fontana, A, Fruhwald, F, Giamouzis, G, Giannakoulas, G, Garcia-Gonzalez, M J, Gustafsson, F, Kaikkonen, K, Kivikko, M, Kubica, J, von Lewinski, D, Lofman, I, Malfatto, G, Manito, N, Martinez-Selles, M, Masip, J, Merkely, B, Morandi, F, Molgaard, H, Oliva, F, Pantev, E, Papp, Z, Perna, G P, Pfister, R, Piazza, V, Bover, R, Rangel-Sousa, D, Recio-Mayoral, A, Reinecke, A, Rieth, A, Sarapohja, T, Schmidt, G, Seidel, M, Stoerk, S, Vrtovec, B, Wikstroem, G, Yerly, P & Pollesello, P 2017, ' Repetitive use of levosimendan in advanced heart failure : need for stronger evidence in a field in dire need of a useful therapy ', International Journal of Cardiology, vol. 243, pp. 389-395 . https://doi.org/10.1016/j.ijcard.2017.05.081
Patients in the latest stages of heart failure are severely compromised, with poor quality of life and frequent hospitalizations. Heart transplantation and left ventricular assist device implantation are viable options only for a minority, and interm
Publikováno v:
European Journal of Heart Failure. 19:1606-1614
Aims As the role of chronic kidney disease (CKD) in different types of heart failure (HF) is poorly understood, our aim was to compare CKD in HF with preserved (HFpEF), mid-range (HFmrEF), and reduced ejection fraction (HFrEF) with regard to prevalen
Publikováno v:
The American journal of cardiology. 124(10)
There are no studies of long-term worsening renal function (WRF) in heart failure (HF) with different ejection fraction (EF) groups. The aim was to compare incidence of, associations with and prognostic impact of WRF in HF with preserved (HFpEF), mid
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background There are no studies of mineralocorticoid receptor antagonist ( MRA ) treatment examining outcome in unselected real‐life patients with myocardial infarction ( MI ) and heart failure ( HF ). There is uncertainty regarding effects of MRA
Autor:
Claes Hofman-Bang, Liyew Desta, Inger Hagerman, Tomas Jernberg, Jonas Spaak, Hans Persson, Ida Löfman
Publikováno v:
JACC: Heart Failure. 3:234-242
Objectives: The aim of this study was to examine temporal trends in the incidence and outcomes of heart failure (HF) complicating acute myocardial infarction (AMI) in a large national cohor...